NPRA Banner

               
Product Search   QUEST3+ System   Enquiries   Sitemap  

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia

As of November 2023, there have been no new locally reported adverse events following immunisation (AEFIs) for COVID-19 vaccines, and the safety profiles of the vaccines have remained consistent. Therefore, the NPRA will cease publishing our periodic summary reports on COVID-19 vaccine safety and reported AEFIs. All previous summary reports remain available on the NPRA website as listed below.

Routine safety monitoring and surveillance of COVID-19 vaccines will continue, with timely communication of any significant emerging safety concerns. To receive the latest updates, join the NPRA Safety Information Mailing List by completing the subscription form.

The NPRA encourages anyone who suspects they have experienced a side effect linked to their COVID-19 vaccine to report it to the NPRA.

Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 30 Nov 2023)

Pengenalan

  • Bagaimana NPRA mengumpul laporan kesan advers?
  • Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?

Jumlah Dos Vaksin COVID-19 Yang Diberikan

Kadar Pelaporan Kesan Advers

  • Respon AEFI yang diterima melalui aplikasi MySejahtera
  • Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
  • Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
  • Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun

Adverse Events of Special Interest (AESI)

Rumusan

  • Manfaat pemberian vaksin COVID-19 melebihi risikonya 
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 30th Nov 2023)

Introduction

  • How does NPRA collect adverse event reports?
  • How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses
  • COVID-19 vaccination in children aged 5 to 11 years

Adverse Events of Special Interest (AESI)

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 30 Apr 2023)

Pengenalan

  • Bagaimana NPRA mengumpul laporan kesan advers?
  • Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?

Jumlah Dos Vaksin COVID-19 Yang Diberikan

Kadar Pelaporan Kesan Advers

  • Respon AEFI yang diterima melalui aplikasi MySejahtera
  • Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
  • Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
  • Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun

Adverse Events of Special Interest (AESI)

Rumusan

  • Manfaat pemberian vaksin COVID-19 melebihi risikonya 
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 30th Apr 2023)

Introduction

  • How does NPRA collect adverse event reports?
  • How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses
  • COVID-19 vaccination in children aged 5 to 11 years

Adverse Events of Special Interest (AESI)

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 31 Dis 2022)

Pengenalan

  • Bagaimana NPRA mengumpul laporan kesan advers?
  • Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?

Jumlah Dos Vaksin COVID-19 Yang Diberikan

Kadar Pelaporan Kesan Advers

  • Respon AEFI yang diterima melalui aplikasi MySejahtera
  • Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
  • Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
  • Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun

Adverse Events of Special Interest (AESI)

Rumusan

  • Manfaat pemberian vaksin COVID-19 melebihi risikonya 
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 31st Dec 2022)

Introduction

  • How does NPRA collect adverse event reports?
  • How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses
  • COVID-19 vaccination in children aged 5 to 11 years

Adverse Events of Special Interest (AESI) 

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 20 Sep 2022)

Pengenalan

  • Bagaimana NPRA mengumpul laporan kesan advers?
  • Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?

Jumlah Dos Vaksin COVID-19 Yang Diberikan

Kadar Pelaporan Kesan Advers

  • Respon AEFI yang diterima melalui aplikasi MySejahtera
  • Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
  • Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
  • Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun

Adverse Events of Special Interest (AESI)

Rumusan

  • Manfaat pemberian vaksin COVID-19 melebihi risikonya 
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 20th Sept 2022)

Introduction

  • How does NPRA collect adverse event reports?
  • How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses
  • COVID-19 vaccination in children aged 5 to 11 years

Adverse Events of Special Interest

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Laporan Ringkas Kesan Advers Susulan Imunisasi (AEFI) Vaksin COVID-19 di Malaysia (Data sehingga 10 Jun 2022)

Pengenalan

  • Bagaimana NPRA mengumpul laporan kesan advers?
  • Bagaimana NPRA memproses laporan AEFI dan memantau keselamatan vaksin COVID-19?

Jumlah Dos Vaksin COVID-19 Yang Diberikan

Kadar Pelaporan Kesan Advers

  • Respon AEFI yang diterima melalui aplikasi MySejahtera
  • Laporan AEFI yang diterima melalui Sistem Pelaporan NPRA
  • Laporan AEFI di kalangan penerima dos penggalak vaksin COVID-19
  • Pelaporan AEFI vaksin COVID-19 bagi golongan remaja berusia 12-17 tahun
  • Pelaporan AEFI vaksin COVID-19 bagi golongan kanak-kanak berusia 5-11 tahun

Adverse Events of Special Interest (AESI)

Rumusan

  • Manfaat pemberian vaksin COVID-19 melebihi risikonya 
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 10th June 2022)

Introduction

  • How does NPRA collect adverse event reports?
  • How does NPRA process AEFI reports and monitor safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses (PICK-B)
  • COVID-19 vaccination in adolescents aged 12 to 17 years
  • COVID-19 vaccination in children aged 5 to 11 years

Adverse Events of Special Interest

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 11th March 2022)

Introduction

  • How NPRA collects adverse event reports?
  • How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • Booster doses (PICK-B)
  • COVID-19 vaccination in children aged 5 to 11 years (PICKids)

Adverse Events of Special Interest

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 31st December 2021)

Introduction

  • How NPRA collects adverse event reports?
  • How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System
  • COVID-19 vaccination in the age of 12 to 17 years
  • Booster doses

Adverse Events of Special Interest 

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

Summary Report on Adverse Events Following Immunisation of COVID-19 Vaccines in Malaysia (Data as of 29th October 2021)

Introduction

  • How NPRA collects adverse event reports?
  • How NPRA processes AEFI reports and monitors safety of COVID-19 vaccines?

Total Doses of COVID-19 Vaccines Administered

Rate of Reported Adverse Events

  • AEFI responses received via MySejahtera application
  • AEFI reports received via NPRA Reporting System

Summary

  • Protective benefits of COVID-19 vaccination outweigh the potential risks
Image

 

National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400

 

 

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Site Last Modified

  • Last Modified: Wednesday 13 November 2024, 12:32:37.

Search

Main Menu English